[Corrigendum] DR2&nbsp;blocker thioridazine:&nbsp;A promising drug for ovarian cancer therapy

Yong,Min; Yu,Tinghe; Tian,Si; Liu,Shuaibin; Xu,Jiao; Hu,Jianguo; Hu,Lina

doi:10.3892/ol.2020.12081

November-2020 Volume 20 Issue 5

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

November-2020 Volume 20 Issue 5

Full Size Image

Correction Open Access

[Corrigendum] DR2 blocker thioridazine: A promising drug for ovarian cancer therapy

Authors:
- Min Yong
- Tinghe Yu
- Si Tian
- Shuaibin Liu
- Jiao Xu
- Jianguo Hu
- Lina Hu
View Affiliations / Copyright

Affiliations: Department of Obstetrics and Gynecology, Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan 637000, P.R. China, Department of Obstetrics and Gynecology, Second Affiliated Hospital, Chongqing Medical University, Chongqing 400010, P.R. China, Department of Rehabilitation, Second Affiliated Hospital, Chongqing Medical University, Chongqing 400010, P.R. China

Copyright: © Yong et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY 4.0].
Article Number: 218
|
Published online on: September 9, 2020

https://doi.org/10.3892/ol.2020.12081
Expand metrics +

Article

Oncol Lett 14: [Related article:] 8171-8177, 2017; DOI: 10.3892/ol.2017.7184

Subsequently to the publication of the above article, and a Corrigendum that has already been published to show corrected versions of Figs. 1 and 2 (DOI: /10.3892/ol.2020.11285; published online on January 9, 2020), the authors have realized that Fig. 4D also featured the incorrect placement of a data panel; essentially, the data panel shown for the A2780, thioridazine experiment was a duplicate of the SKOV3, thioridazine data panel.

Figure 4.

Thioridazine induced autophagy in ovarian cancer cells. (A) LC3 localization following treatment with thioridazine for 12 h (scale bar, 50 μm). (B) Representative western blot analysis demonstrating the expression levels of LC3 following treatment with thioridazine (0, 5, 10 and 15 μM) for 24 h. GAPDH was used as an internal control. (C) Representative western blot analysis demonstrating the expression levels of LC3 and P62 following treatment with 15 μM thioridazine for various lengths of time (0, 6, 12 and 24 h). GAPDH was used as an internal control. (D) Ovarian cancer cells were pre-treated with 5 mM 3-MA for 2 h, and then treated with 15 μM thioridazine for 24 h. Annexin V/PI double staining was used to analyze the effect of thioridazine on ovarian cancer cells. Data are representative of the results of two independent experiments. *P=0.004, **P=0.021 compared with the control group. 3-MA, 3-methyl adenine; NC, negative control; PI, protease inhibitor; LC3, light chain 3.

The corrected version of Fig. 4, featuring the correct data for the A2780, thioridazine experiment, is shown on the next page. All the authors agree to this Corrigendum. Note that the revisions made to these figures do not adversely affect the results reported in the paper, or the conclusions stated therein. The authors regret that this additional error was not noticed prior to the publication of this article, and offer their apologies to the Editor and to the readers of the Journal.